Difference between revisions of "Team:AQA Unesp"

 
(233 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
{{AQA_Unesp_nav}}.
+
{{AQA_Unesp_nav}}
  
 
<html>
 
<html>
−
<head>
+
<body>
−
<meta charset="utf-8">
+
−
<link href="https://fonts.googleapis.com/css?family=Roboto|Muli" rel="stylesheet">
+
−
<title>Team: AQA_Unesp</title>
+
−
<script>
+
−
function changeText1() {
+
−
document.getElementById("text").innerHTML="<img src='https://static.igem.org/mediawiki/2017/3/35/T--AQA_Unesp--administration.png' id='man_title1'> We want our bacteria to be easily taken: our idea is having a final product that can be ingested by a fermented milk or a lyophilized that can be mixed with other beverages, so it can easily taken by children, adults and elder people without causing any discomforts. Once ingested, the bacteria will be set up in the gut, where it will sense and actuate.";
+
  
 +
<style>
 +
 +
.foto-grande {
 +
background: url(https://static.igem.org/mediawiki/2017/6/68/Aqaunesp-main-header.png) no-repeat center center;
 +
width: 100%;
 +
height: 100vh;
 +
overflow:hidden;
 +
background-size: cover;
 +
padding: 5% 0;
 
}
 
}
−
function changeText2() {
+
 
−
document.getElementById("text").innerHTML="<img src='https://static.igem.org/mediawiki/2017/d/d7/T--AQA_Unesp--sensing.png' id='man_title2'> We don’t want to produce insulin the whole time  without any control! So, the bacteria needs to sense and control its production. We will build a control system based on the natural L. lactis system for catabolite repression along with regulation by a small RNA (sRNA).<br>The CcpA protein is the protein responsible for control the gene expression in gram-positive bacteria, this protein is activated when glucose is present and then it binds to the DNA at the catabolite repression site (CRE) and represses the expression of downstream gene. We will put a coding sequence for a sRNA under the control of a promoter containing a CRE site, that targets the RBS site and the start codon of the mRNA coding the insulin gene, blocking its translation.<br>This way, when there is no glucose, the expression of our sRNA will be on and will block the production of insulin. Where there is glucose, the expression of our sRNA will be off and we will have the production of insulin. The produced insulin then is ready to be secreted and absorbed.";
+
@font-face {
 +
    font-family: caviardreams;
 +
    src: url('https://static.igem.org/mediawiki/2017/4/43/Aqaunesp-caviardreams.ttf');
 
}
 
}
−
function changeText3() {
+
 
−
document.getElementById("text").innerHTML="<img src='https://static.igem.org/mediawiki/2017/d/d1/T--AQA_Unesp--actuating.png' id='man_title3'> We need our insulin to be secreted by our bacteria so the insulin gene will have an secretion signal sequence called usp45 which allows L. lactis to secrete proteins. The insulin that we will be using is a single-chain analog called SCI-57 that can be produced by bacteria and maintain its biological activity. Once the insulin is out, it needs to be absorbed by the intestinal epithelium, so our insulin will be associated with cell-penetrating peptides (CPPs) that allow the uptake of the insulin, which will reach the blood and then perform its biological function.";
+
.insubiota-text { font:12em caviardreams, sans-serif; text-align: center; color:white }
 +
 
 +
.insubiota-subtext {  font:2em caviardreams, sans-serif; text-align: center; color:white; }
 +
 
 +
#titleinsubiota {padding: 10% 0;}
 +
 
 +
#abstract { font:5em caviardreams, sans-serif; text-align: center; color: white; font-weight:bold; padding-top: 2%}
 +
 
 +
#gold-award { float:left; }
 +
 
 +
</style>
 +
 
 +
 
 +
<div class="foto-grande">
 +
 
 +
<div id="titleinsubiota">
 +
<div style="width:950px; margin: 0 auto">
 +
 
 +
<img src="https://static.igem.org/mediawiki/2017/e/ec/Gold-award-aqaunesp.png" width="200px" id="gold-award">
 +
<div class="insubiota-text">INSUBIOTA</div>
 +
<div class="insubiota-subtext">treating diabetes with genetically engineered probiotic</div>
 +
 
 +
</div>
 +
</div>
 +
 
 +
</div>
 +
 
 +
<div style="width:100%; margin: 0 auto; background-color: #44558f">
 +
 
 +
<div id="abstract">ABSTRACT</div>
 +
 
 +
<div style="max-width:1000px; font-size:1.5em; margin: 2% auto; line-height:1.5; text-align:justify; color: white; padding-top:2%; padding-bottom: 2%">
 +
Our project was inspired on the alarming and increasing number of diabetic people, especially diabetes mellitus type 1 patients, who are insulin dependent. The lack of less invasive treatments has motivated us to develop a new treatment based on the probiotic bacteria <i>Lactococcus lactis</i>, that was engineered to produce a single-chain analog insulin in human diabetic’s microbiota. The bacteria will be able to produce the insulin associated with a secretion signal sequence and cell-penetrating peptides, to ensure its uptake. Moreover, the synthesis of the insulin will be controlled by the natural bacteria system of catabolite repression with regulation by a small RNA. At the presence of glucose, the insulin gene expression will be activated, and then, it will be ready to be secreted and absorbed, reaching the blood and performing its biological function. Also, in order to contain the release of our engineered probiotic to the environment, we built a kill switch based on light exposure that uses the CRISPR/Cas9 system to destroy essential genes for the bacterial survival. The final product could be a fermented milk or a lyophilized that could be easily ingested by patients.
 +
 
 +
</div>
 +
</div>
 +
 
 +
<div style="text-align:center">
 +
<video width="1000" controls>
 +
<source src="https://static.igem.org/mediawiki/2017/a/a7/Aqaunesp-video-insubiota.mp4" type="video/mp4">
 +
</video>
 +
</div>
 +
 
 +
<style>
 +
#buttons { max-width:1100px; margin:3% auto; display:table}
 +
 
 +
.botao-link {
 +
position: relative;
 +
width: 150px;
 +
float:left;
 +
margin:5px;
 
}
 
}
−
function cleanText() {
+
 
−
document.getElementById("text").innerHTML="In our first time ever participating in iGEM, our project is to develop a new treatment for diabetes mellitus type 1 (DM1). We want to engineer a Lactococcus lactis strain to live in the human gut and produce an insulin analog that can be absorbed by the intestinal epithelium. The number of DM1 patients and deaths due to DM1 is increasing every year and we want to make those people’s life better: no more several insulin injections in a single day!
+
 
−
Our engineered L. lactis will produce a single-chain insulin analog associated with cell-penetrating peptides (CPPs) that facilitate the uptake of insulin by the intestinal epithelium. The expression of insulin will occur under a glucose control built using the catabolite repression system of gram-positive bacteria along with regulation by a small RNA.
+
.image {
−
<b>Mouse over the image to learn more!</b>";
+
  display: block;
 +
  width: 150px;
 +
  height: 150px;
 
}
 
}
−
</script>
 
−
</head>
 
  
−
<body>
+
.overlay {
−
<nav>
+
  position: absolute;
−
<ul class="menu">
+
  top: 0;
−
<li class="logo"><a href="index.html"><img src="https://static.igem.org/mediawiki/2017/3/32/T--AQA_Unesp--logo_sb_small.png"></a></li>
+
  bottom: 0;
−
<li class="item"><a href="#">ENTREPRENEURSHIP</a></li>
+
  left: 0;
−
<li class="item"><a href="#">NOTEBOOK</a></li>
+
  right: 0;
−
<li class="item"><a href="#">INTERLAB</a></li>
+
  height: 100%;
−
<li class="item"><a href="#">TEAM &#9662;</a>
+
  width: 100%;
−
<ul>
+
  opacity: 0;
−
<li><a href="#">Team</a></li>
+
  transition: .5s ease;
−
<li><a href="#">Attributions</a></li>
+
  background-color: #008CBA;
−
<li><a href="#">Collaborations</a></li>
+
border-radius:50%;
−
</ul>
+
}
−
</li>
+
 
−
<li class="item"><a href="hp.html">HUMAN PRACTICES &#9662;</a>
+
#projectdesc {background-color: RGB(255,208,91)}
−
<ul>
+
#design {background-color: RGB(159,159,226)}
−
<li><a href="hp.html">Silver HP</a></li>
+
#hpp {background-color: RGB(50,74,94)}
−
<li><a href="#">Integrated HP</a></li>
+
#team {background-color: RGB(255,76,58)}
−
<li><a href="#">Public Engagement</a></li>
+
 
−
<li><a href="#">Safety</a></li>
+
.botao-link:hover .overlay {
−
</ul>
+
  opacity: 1;
−
</li>
+
}
−
<li class="item"><a href="#">PROJECT &#9662;</a>
+
 
−
<ul>
+
.text {
−
<li><a href="#">Description</a></li>
+
  color: white;
−
<li><a href="#">Design</a></li>
+
  font-size: 20px;
−
<li><a href="#">Model</a></li>
+
  position: absolute;
−
<li><a href="#">Results</a></li>
+
  top: 50%;
−
<li><a href="#">Demonstrate</a></li>
+
  left: 50%;
−
<li><a href="#">Parts</a></li>
+
  transform: translate(-50%, -50%);
−
</ul>
+
  -ms-transform: translate(-50%, -50%);
−
</li>
+
}
−
</ul>
+
 
−
</nav>
+
</style>
−
<div id="content">
+
 
−
<div class="box" id="man">
+
<div id="buttons">
−
<img src="https://static.igem.org/mediawiki/2017/5/59/T--AQA_Unesp--man1_t.png" onMouseOver="changeText1(); this.src='https://static.igem.org/mediawiki/2017/d/da/T--AQA_Unesp--man1.png'" onMouseOut="cleanText(); this.src='https://static.igem.org/mediawiki/2017/5/59/T--AQA_Unesp--man1_t.png'" class="man_img">
+
 
−
<img src="https://static.igem.org/mediawiki/2017/8/88/T--AQA_Unesp--man2_t.png" onMouseOver="changeText2(); this.src='https://static.igem.org/mediawiki/2017/3/30/T--AQA_Unesp--man2.png'" onMouseOut="cleanText(); this.src='https://static.igem.org/mediawiki/2017/8/88/T--AQA_Unesp--man2_t.png'" class="man_img">  
+
<div class="botao-link">
−
<img src="https://static.igem.org/mediawiki/2017/9/96/T--AQA_Unesp--man3_t.png" onMouseOver="changeText3(); this.src='https://static.igem.org/mediawiki/2017/b/b5/T--AQA_Unesp--man3.png'" onMouseOut="cleanText(); this.src='https://static.igem.org/mediawiki/2017/b/b5/T--AQA_Unesp--man3.png'" class="man_img">
+
<a href="https://2017.igem.org/Team:AQA_Unesp/Description">
−
</div>
+
<img src="https://static.igem.org/mediawiki/2017/f/f5/Aqaunesp-projectdescription-icon.png" class="image">
−
<div class="box" id="description">
+
<div class="overlay" id="projectdesc">
−
<img src="https://static.igem.org/mediawiki/2017/6/6a/T--AQA_Unesp--logoInsubiota_index.png">
+
<div class="text">project description</div>
−
<h2 font-color='black'>Treating diabetes with probiotics</h2>
+
</div>
−
<br>
+
</a>
−
<p id="text">
+
</div>
−
In our first time ever participating in iGEM, our project is to develop a new treatment for diabetes mellitus type 1 (DM1). We want to engineer a Lactococcus lactis strain to live in the human gut and produce an insulin analog that can be absorbed by the intestinal epithelium. The number of DM1 patients and deaths due to DM1 is increasing every year and we want to make those people’s life better: no more several insulin injections in a single day!
+
 
−
Our engineered L. lactis will produce a single-chain insulin analog associated with cell-penetrating peptides (CPPs) that facilitate the uptake of insulin by the intestinal epithelium. The expression of insulin will occur under a glucose control built using the catabolite repression system of gram-positive bacteria along with regulation by a small RNA.
+
<div class="botao-link">
−
<b>Mouse over the image to learn more!</b>
+
<a href="https://2017.igem.org/Team:AQA_Unesp/Applied_Design">
−
</p>
+
<img src="https://static.igem.org/mediawiki/2017/c/cd/AQAUnesp-design-icon.png" class="image">
−
</div>
+
<div class="overlay" id="design">
−
</div>
+
<div class="text">design</div>
−
+
</div>
 +
</a>
 +
</div>
 +
 
 +
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/Results">
 +
<img src="https://static.igem.org/mediawiki/2017/7/7c/Aqaunesp-results-icon.png" class="image">
 +
<div class="overlay" id="projectdesc">
 +
<div class="text">results</div>
 +
</div>
 +
</a>
 +
</div>
 +
 
 +
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/HP/Silver">
 +
<img src="https://static.igem.org/mediawiki/2017/0/0a/AQAUnesp-hp-icon.png" class="image">
 +
<div class="overlay" id="hpp">
 +
<div class="text">human practices</div>
 +
</div>
 +
</a>
 +
</div>
 +
 
 +
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/Team">
 +
<img src="https://static.igem.org/mediawiki/2017/b/bd/AQAUnesp-team-icon.png" class="image">
 +
<div class="overlay" id="team">
 +
<div class="text">team</div>
 +
</div>
 +
</a>
 +
</div>
 +
 
 +
</div>
 +
 
 
</body>
 
</body>
 
</html>
 
</html>
 
{{AQA_Unesp_btm}}
 
{{AQA_Unesp_btm}}

Latest revision as of 18:13, 15 December 2017



iGEM AQA_Unesp

INSUBIOTA
treating diabetes with genetically engineered probiotic
ABSTRACT
Our project was inspired on the alarming and increasing number of diabetic people, especially diabetes mellitus type 1 patients, who are insulin dependent. The lack of less invasive treatments has motivated us to develop a new treatment based on the probiotic bacteria Lactococcus lactis, that was engineered to produce a single-chain analog insulin in human diabetic’s microbiota. The bacteria will be able to produce the insulin associated with a secretion signal sequence and cell-penetrating peptides, to ensure its uptake. Moreover, the synthesis of the insulin will be controlled by the natural bacteria system of catabolite repression with regulation by a small RNA. At the presence of glucose, the insulin gene expression will be activated, and then, it will be ready to be secreted and absorbed, reaching the blood and performing its biological function. Also, in order to contain the release of our engineered probiotic to the environment, we built a kill switch based on light exposure that uses the CRISPR/Cas9 system to destroy essential genes for the bacterial survival. The final product could be a fermented milk or a lyophilized that could be easily ingested by patients.
Team: AQA_Unesp